On August 30, 2024, Thyrocare Technologies Limited, a major player in healthcare diagnostics, announced that it had signed a Business Transfer Agreement with Vimta Labs Limited.
This agreement involves Thyrocare acquiring Vimta Labs’ diagnostic and pathological services business.
Key Details Of The Deal
Strategic Reasons Behind The Acquisition
“I am pleased to announce that we are acquiring the diagnostic and pathological services business of Vimta. This strategic move aligns with our growth objectives, allowing Thyrocare to expand its market share, solidify our leadership position in South India, and grow our business with franchisees and hospitals. Additionally, this expansion will enable Thyrocare to leverage the benefits of scale.” said Mr Rahul Guha, MD & CEO of Thyrocare Technologies Limited
Thyrocare Technologies Limited is India’s leading and first fully automated laboratory chain, with a strong presence across the country. Thyrocare is dedicated to offering high-quality, affordable diagnostic services to labs and hospitals throughout India. Numerous labs and hospital brands nationwide rely on the extensive range of tests provided by Thyrocare.
Vimta Labs Limited was originally founded as a partnership firm in 1984. It is India’s most comprehensive contract research and testing organisation, offering various industries a wide range of services. These include biopharmaceuticals, food, consumer goods, electronics, electrical, agrochemicals, healthcare, medical devices, power, cement, oil and gas, ores and minerals, infrastructure, and more.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Aug 30, 2024, 4:06 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates